Phase 2 Lung Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who have been diagnosed with non-small cell lung cancer (a type of lung cancer) that has spread or come back, and whose cancer continued to grow after receiving immunotherapy treatment.
• People whose cancer is considered appropriate for standard treatment with immunotherapy or chemotherapy.
• People who have at least one tumour that can be clearly measured on a scan (CT or MRI), with the largest measurement being at least 10mm, or at least 15mm for affected lymph nodes.
• People who have at least one tumour that is a suitable size and location for a focused, high-dose type of radiation treatment (confirm specific location requirements with trial site).
• People who have received exactly one prior course of a specific type of immunotherapy (called anti-PD-1 or anti-PD-L1 therapy) for their lung cancer, whether given alone or in combination with chemotherapy, another immunotherapy, or a targeted therapy.
• People who received immunotherapy before or after surgery for earlier-stage lung cancer (Stage I–III) may count that as their one prior treatment, depending on how long ago it was given (confirm timing details with trial site).
• People who have certain specific gene mutations in their cancer (BRAF, KRAS, or MET) must have previously received at least one targeted therapy for that mutation, in addition to prior immunotherapy.
• People aged 18 or older.
• People who are well enough to carry out daily activities with no more than moderate limitations, as assessed by their doctor using a standard scale.
• People who are considered well enough to safely receive the study drug combination and standard treatments, as determined by their treating doctor.
• People who have cancer that has spread to the brain, provided their doctor determines that immediate brain-specific treatment is not needed during the first cycle of the study.
• People who have had or currently have another type of cancer, as long as that cancer or its treatment is not expected to interfere with this study.
• People who are able to use reliable contraception (such as hormonal methods, barrier methods, or abstinence) throughout the study and for 3 months after treatment ends, and who agree to inform their doctor immediately if pregnancy occurs or is suspected during the study.
• People who are able to understand and are willing to sign a written consent form agreeing to take part.

Who may not be able to join:

• People whose cancer has certain specific gene mutations (EGFR, ALK, ROS1, RET, NTRK, or HER2), as these mutations are associated with poor response to immunotherapy.
• People who have had lung inflammation (pneumonitis) that was not caused by infection and required steroid treatment.
• People who have a condition causing scarring or inflammation in the lung tissue (interstitial lung disease).
• People who have other serious illnesses that are not currently under control.
• People who are pregnant, as the treatments used in this study are known to carry risks of harm to an unborn baby.
• People who are breastfeeding, as the study treatments may pose unknown risks to a nursing infant.
• People who have previously had radiation treatment to the same area being targeted in this study, if there is significant overlap with the planned radiation area.
• People whose tumours are located in areas where focused radiation cannot be delivered safely, including tumours directly involving the oesophagus, stomach, small bowel, or colon (unless radiation dose limits can still be safely met), or tumours near the spinal cord with less than 3mm of space between the tumour and the spinal cord.

Important: Always verify eligibility with the trial site directly before applying.